www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

US EUROPE AFRICA ASIA 中文
Business / Companies

Xi'an Janssen plans 10 drug launches in four areas by 2020

By Wang Wen (China Daily) Updated: 2015-10-31 09:50

Xi'an Janssen Pharmaceutical Ltd, Johnson & Johnson Services Inc's largest subsidiary in China, plans to launch more than 10 new medicines in China by 2020.

Kris Sterkens, chairman of Jassen Asia Pacific, said innovation remains its core strategy, and its products will be spread over four main treatment areas: tumors, the autoimmune system, mental health and infectious and metabolic diseases such as hepatitis and diabetes.

The firm's new-product strategy, he said, was being supported by a number of recent findings that showed China has strong demand for medicine targeted at those diseases.

A survey by the Economist Intelligence Unit, a global business intelligence belonging to the Economist Group, for instance, analyzed markets in five countries across Asia Pacific including China, and reached the conclusion that "the region now carries a huge global burden of non-communicable diseases, such as cancer and mental illness".

As many as 85 percent of deaths in China in 2010 were the result of non-communicable diseases, according to the report, with cancer, cardiovascular disease and diabetes topping the list of causes.

"Healthcare systems in Asia Pacific are struggling to manage the rise in non-communicable diseases and the shift to long-term treatment of chronic conditions," said Charles Ross, the survey report's editor.

Following on from those and other findings, Xi'an Janssen will launch a new product for prostate cancer soon, said Sterkens. Research is also being conducted on a diabetes medicine.

Xi'an Janssen has launched 14 major new products in the past five years aimed at treating conditions like human immunodeficiency virus, cancer and mental illness.

Established 30 years ago, it has been a regular investor in China since its launch.

A new $290 million plant in Xi'an will be in operation from 2018, said Cesar Rodriguez, the company's chief.

The new site will have an annual capacity of 280 million medicine packages, which will be sold around the world, said Rodriguez.

Xi'an Janssen is well known in China for over-the-counter drugs such as Domperidone and Daktarin.

Johnson & Johnson combined its OTC business in China last year with Xi'an Janssen, a controversial move at the time with some industry commentators fearing the integration might hurt sales.

Rodriguez insisted the integration, named One China OTC, has achieved strong results, although he refused to detail exact numbers.

Hot Topics

Editor's Picks
...
主站蜘蛛池模板: 综合久久91 | 久久国产精品久久久久久 | 国产免费一级片 | 亚洲天堂色视频 | 欧美成人xxx | 九九午夜 | 香蕉久久久久久狠狠色 | 国产在线91精品天天更新 | 韩国三级大全久久网站 | 欧美一区二区在线观看免费网站 | 在线精品国产成人综合第一页 | 亚洲一区二区三区四区五区六区 | 久久视频精品线视频在线网站 | 99视频在线精品免费观看18 | 99av在线 | 久久www免费人成_看片高清 | 国产性精品| 亚洲一区二区三区成人 | 麻豆视频国产 | 一区国严二区亚洲三区 | 国产精品午夜波多野结衣性色 | 99久久精品免费观看区一 | 亚洲高清一区二区三区四区 | 久99久精品视频免费观看v | 三级黄色片在线免费观看 | 国产一级免费 | 亚洲综合91| 久草中文在线 | 手机国产精品一区二区 | 全部孕妇毛片丰满孕妇孕交 | 亚洲天堂免费视频 | 国内精品91最新在线观看 | 久久视频免费在线观看 | 国产在播放一区 | 色一情一乱一乱91av | 日韩视频在线观看一区 | 久久久久香蕉视频 | 国产在线日韩在线 | 国产精品久久久久久搜索 | 欧美午夜在线播放 | 国产成人99精品免费观看 |